gemcitabine has been researched along with everolimus in 21 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (19.05) | 29.6817 |
| 2010's | 15 (71.43) | 24.3611 |
| 2020's | 2 (9.52) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Dillmann, S; Henne-Bruns, D; Keller, F; Klug, F; Mayer, JM; Stracke, S; Tuncyurek, P | 1 |
| Marik, PE; Vahid, B | 1 |
| Hampton, T | 1 |
| Abrams, T; Allen, B; Blaszkowsky, LS; Chan, JA; Clark, JW; Enzinger, PC; Fuchs, CS; Hezel, AF; Meyerhardt, JA; Ryan, DP; Wolpin, BM | 1 |
| Mehta, SP | 1 |
| Chen, CW; Cheng, AL; Chiang, CT; Feng, WC; Gao, M; Hsu, CH; Kuo, SH; Lu, YS; Yeh, LC; Yeh, PY | 1 |
| Brandt, R; Lane, HA; Lassota, P; McSheehy, PM; O'Reilly, T; Wartmann, M | 1 |
| Tanji, N; Yokoyama, M | 1 |
| Arantes-Rodrigues, R; Cardoso, ML; Colaço, A; Gaivão, I; Oliveira, P; Palmeira, C; Pinto-Leite, R; Santos, L | 1 |
| Boeck, S; Haas, M; Heinemann, V; Holdenrieder, S; Kern, C; Nagel, D; Stieber, P; Wittwer, C | 1 |
| Adams, S; Baum, J; Fitzgerald, JB; Harms, BD; Iadevaia, S; Jiao, Y; Johnson, BW; Kohli, N; Lugovskoy, AA; Nielsen, UB; Olivier, KJ; Razlog, M; Rennard, R; Rimkunas, V; Schoeberl, B; Tang, J; Xu, L | 1 |
| Cheng, CC; Chiu, TH; Huang, YT; Lai, PC; Lin, TC | 1 |
| Alberts, SR; Borad, MJ; Costello, BA; Erlichman, C; Kim, GP; Northfelt, DW; Qi, Y | 1 |
| Boeck, S; Bruns, CJ; Heinemann, V; Jauch, KW; Joka, M; Krause, A; Licht, T; Seufferlein, T; Wichert, Gv; Zech, CJ | 1 |
| Matsumoto, K; Onda, T; Yaegashi, N | 1 |
| Dou, QP; Peng, T | 1 |
| Chen, TC; Lin, G; Lin, KJ; Wang, F; Yeh, TS; Yen, TC | 1 |
| Antoniou, G; Bertulli, R; Blay, JY; Brahmi, M; Casali, PG; Collini, P; Dei Tos, AP; Dufresne, A; Fucà, G; Fumagalli, E; Gronchi, A; Grosso, F; Hindi, N; Jones, RL; Le Cesne, A; Mir, O; Provenzano, S; Sanfilippo, R; Sbaraglia, M; Stacchiotti, S | 1 |
| Cheng, Q; Feng, F; Han, M; Jiang, X; Li, B; Li, F; Li, JY; Li, Z; Liu, C; Qin, H; Qiu, Z; Xiong, L; Xu, C; Yi, B; Yu, Y; Zhang, D | 1 |
| Cui, J; Guo, Y; Peng, T; Wu, H; Xiong, J | 1 |
5 review(s) available for gemcitabine and everolimus
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Pulmonary complications of novel antineoplastic agents for solid tumors.
Topics: Antibiotics, Antineoplastic; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents; Bevacizumab; Deoxycytidine; Doxorubicin; Epirubicin; Etoposide; Everolimus; Gemcitabine; Humans; Lung; Lung Diseases; Mitoxantrone; Neoplasms; Pneumonia; Pyrimidines; Risk Factors; Sirolimus; Teniposide; Trastuzumab | 2008 |
Palliative chemotherapy for pancreatic malignancies.
Topics: Adenocarcinoma; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Capecitabine; Deoxycytidine; ErbB Receptors; Erlotinib Hydrochloride; Everolimus; Fluorouracil; Gemcitabine; Humans; Immunosuppressive Agents; Irinotecan; Organoplatinum Compounds; Oxaliplatin; Palliative Care; Pancreatic Neoplasms; Quality of Life; Quinazolines; Sirolimus | 2010 |
Treatment of metastatic renal cell carcinoma and renal pelvic cancer.
Topics: Benzenesulfonates; Carcinoma, Renal Cell; Cisplatin; Deoxycytidine; Everolimus; Gemcitabine; Humans; Indoles; Kidney Neoplasms; Kidney Pelvis; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Pyrroles; Sirolimus; Sorafenib; Sunitinib | 2011 |
Pharmacotherapy for recurrent ovarian cancer: current status and future perspectives.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Carboplatin; Carcinoma, Ovarian Epithelial; Deoxycytidine; Doxorubicin; Everolimus; Female; Folic Acid; Gemcitabine; Humans; Indazoles; Neoplasm Recurrence, Local; Neoplasms, Glandular and Epithelial; Nivolumab; Ovarian Neoplasms; Paclitaxel; Phthalazines; Piperazines; Poly(ADP-ribose) Polymerase Inhibitors; Polyethylene Glycols; Pyrimidines; Quinazolines; Recombinant Fusion Proteins; Sirolimus; Sulfonamides; Topotecan; TOR Serine-Threonine Kinases; Vinca Alkaloids | 2015 |
4 trial(s) available for gemcitabine and everolimus
| Article | Year |
|---|---|
Oral mTOR inhibitor everolimus in patients with gemcitabine-refractory metastatic pancreatic cancer.
Topics: Administration, Oral; Adult; Aged; Deoxycytidine; Drug Resistance, Neoplasm; Everolimus; Female; Gemcitabine; Humans; Male; Middle Aged; Oncogene Protein v-akt; Pancreatic Neoplasms; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Protein Kinases; Signal Transduction; Sirolimus; TOR Serine-Threonine Kinases | 2009 |
Cytokeratin 19-fragments (CYFRA 21-1) as a novel serum biomarker for response and survival in patients with advanced pancreatic cancer.
Topics: Adult; Aged; Albumins; Antigens, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Axitinib; Biomarkers, Tumor; CA-19-9 Antigen; Capecitabine; Carcinoembryonic Antigen; Deoxycytidine; Disease-Free Survival; Erlotinib Hydrochloride; Everolimus; Fluorouracil; Gemcitabine; Humans; Imidazoles; Indazoles; Keratin-19; Middle Aged; Multivariate Analysis; Oximes; Paclitaxel; Palliative Care; Pancreatic Neoplasms; Piperazines; Prospective Studies; Quinazolines; Sirolimus; Sulfonamides; Survival Rate | 2013 |
Phase I trial of everolimus, gemcitabine and cisplatin in patients with solid tumors.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Drug Administration Schedule; Everolimus; Female; Gemcitabine; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Recurrence, Local; Neoplasms; Sirolimus | 2014 |
Combination of antiangiogenic therapy using the mTOR-inhibitor everolimus and low-dose chemotherapy for locally advanced and/or metastatic pancreatic cancer: a dose-finding study.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Cohort Studies; Deoxycytidine; Everolimus; Female; Gemcitabine; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Metastasis; Neovascularization, Pathologic; Pancreas; Pancreatic Neoplasms; Sirolimus; TOR Serine-Threonine Kinases | 2014 |
12 other study(ies) available for gemcitabine and everolimus
| Article | Year |
|---|---|
Everolimus and mycophenolate mofetil sensitize human pancreatic cancer cells to gemcitabine in vitro: a novel adjunct to standard chemotherapy?
Topics: Adenocarcinoma; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Collagen Type I; Deoxycytidine; Drug Synergism; Everolimus; Gemcitabine; Humans; Immunosuppressive Agents; Mycophenolic Acid; Pancreatic Neoplasms; Sirolimus | 2007 |
Clinical trials probe new therapies for some difficult-to-treat cancers.
Topics: Antineoplastic Agents; Brachytherapy; Carcinoma, Renal Cell; Clinical Trials as Topic; Deoxycytidine; Endometrial Neoplasms; Everolimus; Female; Gemcitabine; Humans; Kidney Neoplasms; Male; Pancreatic Neoplasms; Sirolimus | 2008 |
Combinations of mTORC1 inhibitor RAD001 with gemcitabine and paclitaxel for treating non-Hodgkin lymphoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blotting, Western; Caspases; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Dose-Response Relationship, Drug; Drug Synergism; Enzyme Activation; Everolimus; Gemcitabine; Humans; Immunosuppressive Agents; Jurkat Cells; Lymphoma, Non-Hodgkin; Myeloid Cell Leukemia Sequence 1 Protein; Paclitaxel; Proto-Oncogene Proteins c-bcl-2; Signal Transduction; Sirolimus; TOR Serine-Threonine Kinases | 2010 |
Evaluation of the mTOR inhibitor, everolimus, in combination with cytotoxic antitumor agents using human tumor models in vitro and in vivo.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Cell Proliferation; Cisplatin; Deoxycytidine; Dose-Response Relationship, Drug; Doxorubicin; Drug Screening Assays, Antitumor; Drug Synergism; Epothilones; Everolimus; Female; Fluorouracil; Gemcitabine; HCT116 Cells; Humans; Mice; Mice, Nude; Paclitaxel; Sirolimus; TOR Serine-Threonine Kinases; Xenograft Model Antitumor Assays | 2011 |
Everolimus enhances gemcitabine-induced cytotoxicity in bladder-cancer cell lines.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Proliferation; Cell Survival; Comet Assay; Deoxycytidine; DNA Damage; Drug Resistance, Neoplasm; Drug Synergism; Everolimus; Gemcitabine; Humans; Mutagens; Neoplasm Invasiveness; Osmolar Concentration; S Phase; Sirolimus; Urinary Bladder Neoplasms | 2012 |
MM-141, an IGF-IR- and ErbB3-directed bispecific antibody, overcomes network adaptations that limit activity of IGF-IR inhibitors.
Topics: Animals; Antibodies, Bispecific; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Blotting, Western; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Docetaxel; Everolimus; Female; Gemcitabine; Humans; Mice, Inbred NOD; Mice, Nude; Mice, SCID; Neoplasms; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt; Receptor, ErbB-3; Receptor, IGF Type 1; Signal Transduction; Sirolimus; Taxoids; TOR Serine-Threonine Kinases; Tumor Burden; Xenograft Model Antitumor Assays | 2014 |
Therapeutic potential of sepantronium bromide YM155 in gemcitabine-resistant human urothelial carcinoma cells.
Topics: Adenine; Antimetabolites, Antineoplastic; Apoptosis; Autophagy; Carcinoma, Transitional Cell; Cell Line, Tumor; Cell Proliferation; Cyclin-Dependent Kinase Inhibitor p27; Deoxycytidine; DNA Fragmentation; Drug Resistance, Neoplasm; Everolimus; Gemcitabine; Humans; Imidazoles; Inhibitor of Apoptosis Proteins; Ki-67 Antigen; Microtubule-Associated Proteins; Naphthoquinones; Proto-Oncogene Proteins c-bcl-2; Securin; Sirolimus; Survivin; TOR Serine-Threonine Kinases; Urinary Bladder Neoplasms; Urothelium | 2014 |
Everolimus Inhibits Growth of Gemcitabine-Resistant Pancreatic Cancer Cells via Induction of Caspase-Dependent Apoptosis and G
Topics: Apoptosis; Caspase 3; Caspase 7; Cell Line, Tumor; Deoxycytidine; Drug Resistance, Neoplasm; Enzyme Activation; Everolimus; G2 Phase Cell Cycle Checkpoints; Gemcitabine; Humans; M Phase Cell Cycle Checkpoints; Neoplasm Proteins; Pancreatic Neoplasms | 2017 |
Synergistic antiproliferative effects of an mTOR inhibitor (rad001) plus gemcitabine on cholangiocarcinoma by decreasing choline kinase activity.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cholangiocarcinoma; Choline; Choline Kinase; Deoxycytidine; Drug Synergism; Everolimus; Fluorodeoxyglucose F18; Gemcitabine; Humans; Male; Metabolome; Mice; Positron-Emission Tomography; Proton Magnetic Resonance Spectroscopy; Rats, Sprague-Dawley; Signal Transduction; TOR Serine-Threonine Kinases; Xenograft Model Antitumor Assays | 2018 |
Role of Chemotherapy, VEGFR Inhibitors, and mTOR Inhibitors in Advanced Perivascular Epithelioid Cell Tumors (PEComas).
Topics: Adult; Aged; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Everolimus; Female; Gemcitabine; Humans; Indazoles; International Agencies; Male; Middle Aged; Perivascular Epithelioid Cell Neoplasms; Prognosis; Pyrimidines; Retrospective Studies; Sirolimus; Sorafenib; Sulfonamides; Survival Rate; TOR Serine-Threonine Kinases; Vascular Endothelial Growth Factor Receptor-1 | 2019 |
Targeted deep sequencing contributes to guiding personalized targeted therapy for advanced biliary tract cancer patients with non‑radical resection: A real‑world study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Class I Phosphatidylinositol 3-Kinases; Dasatinib; Deoxycytidine; ErbB Receptors; Everolimus; Female; Gemcitabine; Genes, Neoplasm; High-Throughput Nucleotide Sequencing; Humans; Imatinib Mesylate; Lapatinib; Male; Middle Aged; Molecular Targeted Therapy; Mutation; Neoplasm Staging; Organoplatinum Compounds; Receptor, ErbB-2; Receptor, ErbB-3; Receptor, ErbB-4; Survival Rate; Treatment Outcome | 2020 |
Everolimus regulates the activity of gemcitabine-resistant pancreatic cancer cells by targeting the Warburg effect via PI3K/AKT/mTOR signaling.
Topics: Adenosine Triphosphate; Animals; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Movement; Cell Survival; Deoxycytidine; Drug Resistance, Neoplasm; Everolimus; Gemcitabine; Glucose; Humans; Lactic Acid; Male; Mice, Inbred BALB C; Mice, Nude; Pancreatic Neoplasms; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt; Signal Transduction; TOR Serine-Threonine Kinases | 2021 |